Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders

Current Pharmaceutical Design

Volumn 15, Issue 14, 2009, Pages 1595-1611

  Machado Vieira, Rodrigo ^a   Salvadore, Giacomo ^a   Ibrahim, Lobna A ^a   Diaz Granados, Nancy ^a   Zarate Jr , Carlos A ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Mark O Hatfield CRC   (United States)

Author keywords

AMPA; Antidepressant; Bipolar disorder; Depression; Drug development; Glutamate; Metabotropic; NMDA

Indexed keywords

1 AMINOCYCLOPENTANE 1,3,4 TRICARBOXYLIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; ACETYLCYSTEINE; AMN 082; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; CYCLOSERINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; GLUTAMIC ACID; IMIPRAMINE; KETAMINE; LAMOTRIGINE; LITHIUM; MEMANTINE; METABOTROPIC RECEPTOR; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; N,N' DIBENZYHYDRYLETHANE 1,2 DIAMINE; PLACEBO; RILUZOLE; TALAGLUMETAD; TIANEPTINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; GLUTAMIC ACID DERIVATIVE; TRANQUILIZER;

ADD ON THERAPY; ALZHEIMER DISEASE; AMINO ACID METABOLISM; AMINO ACID TRANSPORT; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; ARTHRALGIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BRAIN LEVEL; CATATONIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONTINUOUS INFUSION; DEPRESSION; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRUG TRANSFORMATION; ELECTROCONVULSIVE THERAPY; FATIGUE; GENERALIZED ANXIETY DISORDER; GLIA CELL; GLUTAMATERGIC NEUROTRANSMISSION; GLUTAMATERGIC SYSTEM; HEARTBURN; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; NAUSEA; NERVOUS SYSTEM; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PSYCHOPHARMACOTHERAPY; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; WEIGHT REDUCTION; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; DRUG DELIVERY SYSTEMS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMATES; HUMANS; MOOD DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 67650604592     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788168010     Document Type: Review

References (156)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
2. Dunn V, Goodyer IM. Longitudinal investigation into childhood- and adolescence-onset depression: Psychiatric outcome in early adulthood. Br J Psychiatry 2006; 188: 216-22.
3. Tohen M, Strakowski SM, Zarate C, Jr., Hennen J, Stoll AL, Suppes T, et al. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry 2000; 48: 467-76.
4. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 1996; 274: 740-3.
5. Tohen M, Zhang F, Taylor CC, Burns P, Zarate C, Sanger T, et al. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. J Affect Disord 2001; 65: 85-93.
6. Zarate CA, Jr., Tohen M. Antipsychotic drug treatment in first-episode mania: A 6-month longitudinal study. J Clin Psychiatry 2000; 61: 33-8
7. Baldessarini RJ, Hennen J, Wilson M, Calabrese J, Chengappa R, Keck PE, Jr., et al. Olanzapine versus placebo in acute mania: Treatment responses in subgroups. J Clin Psychopharmacol 2003; 23: 370-6.
8. Zarate CA, Jr., Quiroz JA. Combination treatment in bipolar disorder: A review of controlled trials. Bipolar Disord 2003; 5: 217-25.
9. McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, et al. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 2004; 65: 204-10
10. Zarate CA, Jr., Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004; 161: 169-71.
11. Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006; 8: 232-41.
12. Zarate CA, Jr., Tohen M, Narendran R, Tomassini EC, McDonald J, Sederer M, et al. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: A pharmacoepidemiology study. J Clin Psychiatry 1999; 60: 232-6.
13. Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1965; 122: 509-22.
14. Manji HK, Zarate CA. Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: Implications for the development of improved therapeutics. Mol Psychiatry 2002; 7(Suppl 1): S1-7.
15. Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 2006; 11: 11-7.
16. Agid Y, Buzsaki G, Diamond DM, Frackowiak R, Giedd J, Girault JA, et al. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 2007; 6: 189-201.
17. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006; 163: 28-40.
18. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292: 338-43.
19. Zarate CA, Jr., Singh J, Manji HK. Cellular plasticity cascades: Targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006; 59: 1006-20.
20. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, N AG, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-42.
21. Carlson PJ, Singh JB, Zarate CA, Jr., Drevets WC, Manji HK. Neural circuitry and neuroplasticity in mood disorders: Insights for novel therapeutic targets. NeuroRx 2006; 3: 22-41.
22. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58: 545-53.
23. Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord 2002; 4: 105-16.
24. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 2007; 18: 391-418.
25. Quiroz JA, Gray NA, Kato T, Manji HK. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008; 33:2551-65.
26. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008; 7: 426-37.
27. Quiroz JA, Singh J, Gould TD, Denicoff KD, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: Clues from the molecular pathophysiology. Mol Psychiatry 2004; 9: 756-76.
28. Javitt DC, Zukin SR. The role of excitatory amino acids in neuropsychiatric illness. J Neuropsychiatry Clin Neurosci 1990; 2: 44-52.
29. Rajkowska G. Histopathology of the prefrontal cortex in major depression: What does it tell us about dysfunctional monoaminergic circuits? Prog Brain Res 2000; 126: 397-412.
30. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999; 375: 31-40.
31. Skolnick P, Legutko B, Li X, Bymaster FP. Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res 2001; 43: 411-23.
32. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-4.
33. Zarate CA, Quiroz J, Payne J, Manji HK. Modulators of the glutamatergic system: Implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002; 36: 35-83.
34. Takamori S, Rhee JS, Rosenmund C, Jahn R. Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature 2000; 407: 189-94.
35. Fremeau RT, Jr., Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, et al. The expression of vesicular glutamate transporters defines two classes of excitatory synapse. Neuron 2001; 31: 247-60.
36. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001; 65: 1-105.
37. Masson J, Sagne C, Hamon M, El Mestikawy S. Neurotransmitter transporters in the central nervous system. Pharmacol Rev 1999; 51: 439-64.
38. Thompson CM, Davis E, Carrigan CN, Cox HD, Bridges RJ, Gerdes JM. Inhibitor of the glutamate vesicular transporter (VGLUT). Curr Med Chem 2005; 12: 2041-56.
39. Tordera RM, Pei Q, Sharp T. Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment. J Neurochem 2005; 94: 875-83.
40. Moutsimilli L, Farley S, Dumas S, El Mestikawy S, Giros B, Tzavara ET. Selective cortical VGLUT1 increase as a marker for antidepressant activity. Neuropharmacology 2005; 49: 890-900.
41. Kang TC, Kim DS, Kwak SE, Kim JE, Kim DW, Kang JH, et al. Valproic acid reduces enhanced vesicular glutamate transporter immunoreactivities in the dentate gyrus of the seizure prone gerbil. Neuropharmacology 2005; 49: 912-21.
42. Tordera RM, Totterdell S, Wojcik SM, Brose N, Elizalde N, Lasheras B, et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci 2007; 25: 281-90.
43. Bonanno G, Giambelli R, Raiteri L, Tiraboschi E, Zappettini S, Musazzi L, et al. Chronic antidepressants reduce depolarizationevoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005; 25: 3270-9.
44. Prica C, Hascoet M, Bourin M. Antidepressant-like effect of lamotrigine is reversed by veratrine: A possible role of sodium channels in bipolar depression. Behav Brain Res 2008; 191: 49-54.
45. Kaster MP, Raupp I, Binfare RW, Andreatini R, Rodrigues AL. Antidepressant-like effect of lamotrigine in the mouse forced swimming test: Evidence for the involvement of the noradrenergic system. Eur J Pharmacol 2007; 565: 119-24.
46. Banasr M, Chowdhury G, Duman RS, Behar K, Sanacora G. Antidepressant-like effects in the unpredictable stress paradigm. Neuropsychopharmacology 2006; 31: S159-S-160.
47. Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 1993; 250: 473-6.
48. Lingamaneni R, Hemmings HC, Jr. Effects of anticonvulsants on veratridine- and KCl-evoked glutamate release from rat cortical synaptosomes. Neurosci Lett 1999; 276: 127-30.
49. Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Kuno S. Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neurosci Lett 2001; 310: 117-20.
50. Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi IK, Inaguma Y, et al. Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J 2002; 16: 1328-30.
51. Zarate CA, Jr., Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004; 161: 171-4.
52. Zarate CA, Jr., Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, et al. An open-label trial of the glutamatemodulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005; 57: 430-2.
53. Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61: 822-5.
54. Lourenco Da Silva A, Hoffmann A, Dietrich MO, Dall'Igna OP, Souza DO, Lara DR. Effect of riluzole on MK-801 and amphetamine-induced hyperlocomotion. Neuropsychobiology 2003; 48: 27-30.
55. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468-75.
56. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002; 20: 171-5.
57. Andreazza AC, Cassini C, Rosa AR, Leite MC, de Almeida LM, Nardin P, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007; 41: 523-9.
58. Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002; 22: 9134-41.
59. Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA. Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993; 265: 1380-6.
60. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994; 269: 95-102.
61. Zarate CA, Jr., Du J, Quiroz J, Gray NA, Denicoff KD, Singh J, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: Role of the glutamatergic system. Ann N Y Acad Sci 2003; 1003: 273-91.
62. Bleakman D, Lodge D. Neuropharmacology of AMPA and kainate receptors. Neuropharmacology 1998; 37: 1187-204.
63. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994; 17: 31-108.
64. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992; 258: 597-603.
65. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996; 29: 23-6.
66. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998; 9: 2081-4.
67. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: Involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002; 80: 589-97.
68. Aguado L, San Antonio A, Perez L, del Valle R, Gomez J. Effects of the NMDA receptor antagonist ketamine on flavor memory: Conditioned aversion, latent inhibition, and habituation of neophobia. Behav Neural Biol 1994; 61: 271-81.
69. Silvestre JS, Nadal R, Pallares M, Ferre N. Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress Anxiety 1997; 5: 29-33.
70. Mickley GA, Schaldach MA, Snyder KJ, Balogh SA, Len T, Neimanis K, et al. Ketamine blocks a conditioned taste aversion (CTA) in neonatal rats. Physiol Behav 1998; 64: 381-90.
71. Adamec RE, Burton P, Shallow T, Budgell J. Unilateral block of NMDA receptors in the amygdala prevents predator stress-induced lasting increases in anxiety-like behavior and unconditioned startle-effective hemisphere depends on the behavior. Physiol Behav 1999; 65: 739-51.
72. Maeng S, Zarate CA, Jr., Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349-52.
73. Zarate CA, Jr., Charney DS, Manji HK. Searching for rational anti-N-methyl-D-aspartate treatment for depression. Arch Gen Psychiatry 2007; 64: 1100-1101.
74. McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff JH. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 2007; 1127: 108-18.
75. Kristiansen LV, Meador-Woodruff JH. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 2005; 78: 87-93.
76. Clinton SM, Meador-Woodruff JH. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 2004; 29: 1353-62.
77. Toro C, Deakin JF. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 2005; 80: 323-30.
78. Karolewicz B, Szebeni K, Gilmore T, Maciag D, Stockmeier CA, Ordway GA. Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol 2008: 1-11.
79. Beneyto M, Meador-Woodruff JH. Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia. Synapse 2006; 60: 585-98.
80. Heresco-Levy U, Javitt DC, Gelfin Y, Gorelik E, Bar M, Blanaru M, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord 2006; 93: 239-43.
81. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63: 49-54.
82. Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev 2003: CD003154.
83. Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993; 72: 394-7.
84. Rogoz Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology 2002; 42: 1024-30.
85. Teng CT, Demetrio FN. Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder. Rev Bras Psiquiatr 2006; 28: 252-4.
86. Munoz C, Yulan N, Achaval V, Appiani F, Carroll BT. Memantine in major depression with catatonic features. J Neuropsychiatry Clin Neurosci 2008; 20: 119-20.
87. Zarate CA, Jr., Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006; 163: 153-5.
88. Muhonen LH, Lonnqvist J, Juva K, Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008; 69: 392-9.
89. Harrison NL, Simmonds MA. Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol 1985; 84: 381-91.
90. Green SM, Rothrock SG, Harris T, Hopkins GA, Garrett W, Sherwin T. Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases. Acad Emerg Med 1998; 5: 971-6.
91. Perry EB, Jr., Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) 2007; 192: 253-60.
92. Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-64.
93. Liebrenz M, Borgeat A, Leisinger R, Stohler R. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly 2007; 137: 234-6.
94. Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J Ect 2007; 23: 23-5.
95. Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. Am J Psychiatry 2005; 162: 1385-6.
96. Correll GE, Futter GE. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Med 2006; 7: 92-5.
97. Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002; 95: 114-8.
98. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997; 17: 2921-7.
99. Suetake-Koga S, Shimazaki T, Takamori K, Chaki S, Kanuma K, Sekiguchi Y, et al. In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist. Pharmacol Biochem Behav 2006; 84: 134-41.
100. Borza I, Bozo E, Barta-Szalai G, Kiss C, Tarkanyi G, Demeter A, et al. Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem 2007; 50: 901-14.
101. Liverton NJ, Bednar RA, Bednar B, Butcher JW, Claiborne CF, Claremon DA, et al. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist. J Med Chem 2007; 50: 807-19.
102. Boyce-Rustay JM, Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 2006; 31: 2405-14.
103. Zarate CA, Jr., Manji HK. The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases. Exp Neurol 2008; 211: 7-10.
104. Sheng M, Sala C. PDZ domains and the organization of supramolecular complexes. Annu Rev Neurosci 2001; 24: 1-29.
105. Song I, Huganir RL. Regulation of AMPA receptors during synaptic plasticity. Trends Neurosci 2002; 25: 578-88.
106. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 2002; 25: 103-26.
107. Rothman JE. Mechanisms of intracellular protein transport. Nature 1994; 372: 55-63.
108. Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA 2002; 99: 3182-7.
109. Stoll L, Seguin S, Gentile L. Tricyclic antidepressants, but not the selective serotonin reuptake inhibitor fluoxetine, bind to the S1S2 domain of AMPA receptors. Arch Biochem Biophys 2007; 458: 213-9.
110. Song I, Kamboj S, Xia J, Dong H, Liao D, Huganir RL. Interaction of the N-ethylmaleimide-sensitive factor with AMPA receptors. Neuron 1998; 21: 393-400.
111. Barbon A, Popoli M, La Via L, Moraschi S, Vallini I, Tardito D, et al. Regulation of editing and expression of glutamate alpha-aminopropionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol Psychiatry 2006; 59: 713-20.
112. Kasper S, McEwen BS. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 2008; 22: 15-26.
113. Svenningsson P, Bateup H, Qi H, Takamiya K, Huganir RL, Spedding M, et al. Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine. Eur J Neurosci 2007; 26: 3509-17.
114. Wong ML, Smith MA, Licinio J, Doi SQ, Weiss SR, Post RM, et al. Differential effects of kindled and electrically induced seizures on a glutamate receptor (GluR1) gene expression. Epilepsy Res 1993; 14: 221-7.
115. Naylor P, Stewart CA, Wright SR, Pearson RC, Reid IC. Repeated ECS induces GluR1 mRNA but not NMDAR1A-G mRNA in the rat hippocampus. Brain Res Mol Brain Res 1996; 35: 349-53.
116. Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: Relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007; 32: 793-802
117. Debono MW, Le Guern J, Canton T, Doble A, Pradier L. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 1993; 235: 283-9.
118. Du J, Gray NA, Falke CA, Chen W, Yuan P, Szabo ST, et al. Modulation of synaptic plasticity by antimanic agents: The role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci 2004; 24: 6578-89.
119. Chourbaji S, Vogt MA, Fumagalli F, Sohr R, Frasca A, Brandwein C, et al. AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. FASEB J 2008; 22: 3129-34.
120. Borges K, Dingledine R. AMPA receptors: Molecular and functional diversity. Prog Brain Res 1998; 116: 153-70.
121. Miu P, Jarvie KR, Radhakrishnan V, Gates MR, Ogden A, Ornstein PL, et al. Novel AMPA receptor potentiators LY392098 and LY404187: Effects on recombinant human AMPA receptors in vitro. Neuropharmacology 2001; 40: 976-83.
122. Meador-Woodruff JH, Hogg AJ, Jr., Smith RE. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res Bull 2001; 55: 631-40.
123. Scarr E, Pavey G, Sundram S, MacKinnon A, Dean B. Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder. Bipolar Disord 2003; 5: 257-64.
124. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007; 164: 1181-8.
125. Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003; 140: 1-47.
126. Salinska E, Stafiej A. Metabotropic glutamate receptors (mGluRs) are involved in early phase of memory formation: Possible role of modulation of glutamate release. Neurochem Int 2003; 43: 469-74.
127. Tan Y, Hori N, Carpenter DO. The mechanism of presynaptic longterm depression mediated by group I metabotropic glutamate receptors. Cell Mol Neurobiol 2003; 23: 187-203.
128. Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164: 1530-8.
129. Menke A, Lucae S, Kloiber S, Horstmann S, Bettecken T, Uhr M, et al. Genetic markers within glutamate receptors associated with antidepressant treatment-emergent suicidal ideation. Am J Psychiatry 2008; 165: 917-8.
130. Palucha A, Branski P, Klak K, Sowa M. Chronic imipramine treatment reduces inhibitory properties of group II mGlu receptors without affecting their density or affinity. Pharmacol Rep 2007; 59: 525-30.
131. Li X, Need AB, Baez M, Witkin JM. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006; 319: 254-9.
132. Wieronska JM, Szewczyk B, Branski P, Palucha A, Pilc A. Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 2002; 23: 213-6.
133. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, et al. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: A potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 2003; 46: 204-6.
134. Belozertseva IV, Kos T, Popik P, Danysz W, Bespalov AY. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007; 17: 172-9.
135. Yoshimizu T, Shimazaki T, Ito A, Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 2006; 186: 587-93.
136. Karasawa J, Shimazaki T, Kawashima N, Chaki S. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 2005; 1042: 92-8.
137. Gasparini F, Bruno V, Battaglia G, Lukic S, Leonhardt T, Inderbitzin W, et al. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. J Pharmacol Exp Ther 1999; 289: 1678-87.
138. Klak K, Palucha A, Branski P, Sowa M, Pilc A. Combined administration of PHCCC, a positive allosteric modulator of mGlu4 receptors and ACPT-I, mGlu III receptor agonist evokes antidepressantlike effects in rats. Amino Acids 2007; 32: 169-72.
139. Cryan JF, Kelly PH, Neijt HC, Sansig G, Flor PJ, van Der Putten H. Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci 2003; 17: 2409-17.
140. Palucha A, Tatarczynska E, Branski P, Szewczyk B, Wieronska JM, Klak K, et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology 2004; 46: 151-9.
141. Palucha A, Klak K, Branski P, van der Putten H, Flor PJ, Pilc A. Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl) 2007; 194: 555-62.
142. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008; 33: 1603-10.
143. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, et al. Altered cortical glutamatergic and GABAergic signal trans USA 2005; 102: 15653-8.
144. McCullumsmith RE, Meador-Woodruff JH. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 2002; 26: 368-75.
145. Fumagalli E, Funicello M, Rauen T, Gobbi M, Mennini T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur J Pharmacol 2008; 578: 171-6.
146. Azbill RD, Mu X, Springer JE. Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res 2000; 871: 175-80
147. Frizzo ME, Dall'Onder LP, Dalcin KB, Souza DO. Riluzole enhances glutamate uptake in rat astrocyte cultures. Cell Mol Neurobiol 2004; 24: 123-8.
148. Ueda Y, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis. Exp Brain Res 2000; 133: 334-9.
149. Hassel B, Iversen EG, Gjerstad L, Tauboll E. Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J Neurochem 2001; 77: 1285-92.
150. Mineur YS, Picciotto MR, Sanacora G. Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry 2007; 61: 250-2.
151. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005; 433: 73-7.
152. Coric V, Milanovic S, Wasylink S, Patel P, Malison R, Krystal JH. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) 2003; 167: 219-20.
153. Singh J, Zarate CA, Jr., Krystal AD. Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology (Berl) 2004; 173: 227-8.
154. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 2008; 14(23): 2279-88.
155. Muller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008; 14(14): 1452-65.
156. Simola N, Morelli M, Pinna A. Adenosine A2A receptor antagonists and Parkinson's disease: State of the art and future directions. Curr Pharm Des 2008; 14(15): 1475-89.